User profiles for "author:Thomas Marjot"

Dr Thomas Marjot

University of Oxford
Verified email at ndm.ox.ac.uk
Cited by 3795

[HTML][HTML] COVID-19 and liver disease: mechanistic and clinical perspectives

T Marjot, GJ Webb, AS Barritt IV, AM Moon… - Nature reviews …, 2021 - nature.com
Our understanding of the hepatic consequences of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection and its resultant coronavirus disease 2019 (COVID …

[HTML][HTML] Non-alcoholic fatty liver disease and diabetes

JM Hazlehurst, C Woods, T Marjot, JF Cobbold… - Metabolism, 2016 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

[HTML][HTML] Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

T Boettler, T Marjot, PN Newsome, MU Mondelli… - JHEP Reports, 2020 - Elsevier
During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and
ESCMID published a position paper to provide guidance for physicians involved in the care …

[HTML][HTML] FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

T Brevini, M Maes, GJ Webb, BV John, CD Fuchs… - Nature, 2023 - nature.com
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-
converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for …

[HTML][HTML] Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

T Marjot, AM Moon, JA Cook, S Abd-Elsalam… - Journal of …, 2021 - Elsevier
Background & Aims Chronic liver disease (CLD) and cirrhosis are associated with immune
dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes …

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry

AM Moon, GJ Webb, C Aloman… - Journal of …, 2020 - journal-of-hepatology.eu
[1] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet …

[HTML][HTML] Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

GJ Webb, T Marjot, JA Cook, C Aloman… - The lancet …, 2020 - thelancet.com
Background Despite concerns that patients with liver transplants might be at increased risk
of adverse outcomes from COVID-19 because of coexisting comorbidities and use of …

Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

T Marjot, A Moolla, JF Cobbold, L Hodson… - Endocrine …, 2020 - academic.oup.com
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

T Marjot, CS Eberhardt, T Boettler, LS Belli… - Journal of …, 2022 - Elsevier
The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …

[HTML][HTML] SARS-CoV-2 infection in patients with autoimmune hepatitis

T Marjot, G Buescher, M Sebode, E Barnes… - Journal of …, 2021 - Elsevier
Background & Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the …